We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00494923
Recruitment Status : Recruiting
First Posted : July 2, 2007
Last Update Posted : December 12, 2013
Sponsor:
Collaborator:
German Research Foundation
Information provided by (Responsible Party):
University of Erlangen-Nürnberg Medical School

Brief Summary:
The Erlangen Glaucoma Registry is a clinical registry for cross sectional and longitudinal observation of patients with open angle glaucoma (OAG) or glaucoma suspect, founded in 1991. The primary aim is the evaluation of diagnostic and prognostic validity of morphometrical, sensory and hemodynamical diagnostic procedures. No therapeutic studies are performed.

Condition or disease
Primary Open Angle Glaucoma Secondary Open Angle Glaucoma Ocular Hypertension

Detailed Description:
Purpose: Detection of onset and progression of structural and functional damage due to glaucoma. Determination of rate and amount of progressive change due to glaucoma. Characterisation of the relationship between structural and functional change over time. Evaluation of predictive factors for the development and progression of glaucoma.

Study Type : Observational
Estimated Enrollment : 2500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)
Study Start Date : January 1999
Estimated Primary Completion Date : December 2015
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources




Primary Outcome Measures :
  1. Time to Disease Progression [ Time Frame: up to 20 years ]

Biospecimen Retention:   Samples With DNA
whole blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic
Criteria

Participants:

  • Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX or MDS, glaucoma suspects including ocular hypertension
  • Healthy volunteers (for cross sectional analysis only)

Inclusion Criteria:

  • Open anterior chamber angle
  • Best corrected visual acuity 0.7 or better
  • Age between 18 and 65 years

Exclusion Criteria:

  • Any eye disease other than glaucoma
  • Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus)
  • Myopic or hyperopic refractive error exceeding 8.0 diopters

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00494923


Contacts
Contact: Anselm G Juenemann, Prof. **49-9131-8533001 anselm.juenemann@uk-erlangen.de

Locations
Germany
University Eye Hospital Recruiting
Erlangen, Germany, 91054
Contact: Robert Laemmer, MD    **49-9131-8533001    robert.laemmer@uk-erlangen.de   
Principal Investigator: Christian Y Mardin, Prof.         
Principal Investigator: Folkert K Horn, PhD         
Principal Investigator: Georg Michelson, Prof.         
Sponsors and Collaborators
University of Erlangen-Nürnberg Medical School
German Research Foundation
Investigators
Study Chair: Anselm G Juenemann, Prof. University Erlangen-Nuremberg

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier: NCT00494923     History of Changes
Other Study ID Numbers: DFG-SFB539-R
First Posted: July 2, 2007    Key Record Dates
Last Update Posted: December 12, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases